Robust equity market conditions and a surge in S-1 filings have supported a rebound in IPO activity through late 2026, with multiple U.S. listings already priced in early October and additional offerings scheduled for mid-month, including Iambic Therapeutics and City Therapeutics. Biotech and AI-related candidates dominate the pipeline amid improved risk appetite and lower withdrawal rates compared with prior years. Trader consensus on near-term IPOs reflects this momentum, though outcomes remain sensitive to upcoming inflation data, Fed communications, and any shifts in Treasury yields that could alter issuance windows before year-end.